Carisma Therapeutics (CARM) to Release Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is anticipated to post its quarterly earnings results before the market opens on Monday, March 31st. Analysts expect Carisma Therapeutics to post earnings of ($0.17) per share and revenue of $5.42 million for the quarter.

Carisma Therapeutics Stock Performance

NASDAQ CARM opened at $0.36 on Friday. The firm has a market cap of $14.94 million, a P/E ratio of -0.23 and a beta of 1.55. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The company’s 50 day moving average is $0.44 and its 200-day moving average is $0.68. Carisma Therapeutics has a 12-month low of $0.35 and a 12-month high of $2.36.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Robert W. Baird lowered shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Carisma Therapeutics in a report on Monday, January 13th. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Carisma Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.94.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.